B-CELL MALIGNANCY
Clinical trials for B-CELL MALIGNANCY explained in plain language.
Never miss a new study
Get alerted when new B-CELL MALIGNANCY trials appear
Sign up with your email to follow new studies for B-CELL MALIGNANCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to wipe out cancer protein in Tough-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough blood cancers? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called HRS-3005 in 190 adults with B-cell blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at wheth…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New BTK-Degrader cocktail takes on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new oral drug called BGB-16673, which breaks down a protein that helps cancer cells grow, in combination with other cancer drugs. It is for people with B-cell cancers (like certain lymphomas) that have come back or stopped responding to treatment. The tria…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug targets Hard-to-Treat blood cancers in chinese trial
Disease control Recruiting nowThis study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two other treatments. The study aims to find the safest dose and check…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1 • Sponsor: Carna Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
CRISPR gene editing takes on blood cancers: new trial tests donor immune cells
Disease control Recruiting nowThis study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC